We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01150942
First Posted: June 25, 2010
Last Update Posted: January 30, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Seoul National University Hospital
Gachon University Gil Medical Center
Inha University Hospital
Inje University
Korea Cancer Center Hospital
Samsung Medical Center
The Catholic University of Korea
Ewha Womans University
Wonju Severance Christian Hospital
Kyunghee University Medical Center
Information provided by (Responsible Party):
Boryung Pharmaceutical Co., Ltd
  Purpose
To assess the immunogenicity and safety of the vero cell-derived inactivated JE vaccine in Korean healthy children aged 12~23 months

Condition Intervention Phase
Japanese Encephalitis Biological: JE vaccine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multi-center, Active-control, Randomized, Double-blind Phase 3 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine 'KD-287(JEIMMUGEN INJ.) in Korean Healthy Children Aged 12~23 Months

Resource links provided by NLM:


Further study details as provided by Boryung Pharmaceutical Co., Ltd:

Primary Outcome Measures:
  • immunogenicity [ Time Frame: pre-dose, after 3rd vaccination ]
    the seroconversion rates for JE antibodies 4 weeks after 3rd vaccination


Enrollment: 205
Study Start Date: August 2010
Study Completion Date: February 2013
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: vero cell-derived JE vaccine
vero cell-derived vaccine group
Biological: JE vaccine
3 times, IM
Active Comparator: Mouse brain-derived JE vaccine
Mouse brain-derived JE vaccine group
Biological: JE vaccine
3 times, IM

Detailed Description:
To compare the Vero cell-derived inactivated Japanese encephalitis(JE) vaccine 'KD-287(JEIMMUGEN INJ.)' with the mouse brain-derived inactivated JE vaccine in terms of the immunogenicity and safety, in Korean healthy children aged 12~23 months
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Months to 23 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy children aged 12-23 months
  • Written informed consent

Exclusion Criteria:

  • History of documented HIV
  • Known or suspected impairment of immunologic function
  • History of serious chronic disease
  • Received any JE vaccine prior to enrollment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01150942


Locations
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Boryung Pharmaceutical Co., Ltd
Seoul National University Hospital
Gachon University Gil Medical Center
Inha University Hospital
Inje University
Korea Cancer Center Hospital
Samsung Medical Center
The Catholic University of Korea
Ewha Womans University
Wonju Severance Christian Hospital
Kyunghee University Medical Center
Investigators
Principal Investigator: Hoan Jong Lee, PhD Seoul National University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Boryung Pharmaceutical Co., Ltd
ClinicalTrials.gov Identifier: NCT01150942     History of Changes
Other Study ID Numbers: KD287-BR-CT-301
First Submitted: June 24, 2010
First Posted: June 25, 2010
Last Update Posted: January 30, 2014
Last Verified: February 2011

Keywords provided by Boryung Pharmaceutical Co., Ltd:
JEV
vero cell

Additional relevant MeSH terms:
Encephalitis
Encephalitis, Japanese
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Encephalitis, Arbovirus
Arbovirus Infections
Virus Diseases
Encephalitis, Viral
Central Nervous System Viral Diseases
RNA Virus Infections
Flavivirus Infections
Flaviviridae Infections
Infectious Encephalitis
Central Nervous System Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs